<DOC>
<DOCNO>EP-0648741</DOCNO> 
<TEXT>
<INVENTION-TITLE>
1,2,3,4-Tetrahydronaphthalene, chroman and thiochroman derivatives as antithrombotic agents
</INVENTION-TITLE>
<CLASSIFICATIONS>C07D33506	C07C31114	A61P4300	A61K3138	A61K3138	C07C31120	A61P4300	C07C31102	A61K31352	C07C31129	A61K31382	A61K3135	A61K31382	A61P702	A61P700	C07D31100	C07D21355	A61K3118	A61P900	A61P900	C07D21300	A61K3118	C07C31100	A61K3135	C07D31158	A61K31352	C07D33500	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>C07D	C07C	A61P	A61K	A61K	C07C	A61P	C07C	A61K	C07C	A61K	A61K	A61K	A61P	A61P	C07D	C07D	A61K	A61P	A61P	C07D	A61K	C07C	A61K	C07D	A61K	C07D	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>C07D335	C07C311	A61P43	A61K31	A61K31	C07C311	A61P43	C07C311	A61K31	C07C311	A61K31	A61K31	A61K31	A61P7	A61P7	C07D311	C07D213	A61K31	A61P9	A61P9	C07D213	A61K31	C07C311	A61K31	C07D311	A61K31	C07D335	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
Compounds of formula (I): 
<
IMAGE
>
  in which:   R1 and R2, which are identical or different, represent a hydrogen or halogen atom or an alkyl, phenyl, which is substituted or unsubstituted, benzyl, pyridylmethyl or imidazolylmethyl, thiazolylmethyl, pyridyl, imidazolyl or thiazolyl group, or else R1 and R2 form, with the carbon atoms to which they are attached, a cyclopentane or cyclohexane ring, R3 represents a hydroxyl, linear or branched (C1-C6)alkoxy or substituted or unsubstituted amino group, R4 represents an alkyl, phenyl, which is substituted or unsubstituted, naphthyl, pyridyl or thienyl group,   X represents a methylene group or an oxygen or sulphur atom, their enantiomers and their addition salts with a pharmaceutically acceptable base. Medicaments.
</ABSTRACT>
<APPLICANTS>
</APPLICANTS>
<INVENTORS>
</INVENTORS>
<CLAIMS>
Compounds of formula (I) : 

 
wherein : 


R
1
, R
2
,
which are identical or different, each represents 
a hydrogen atom, a halogen atom, a straight-chain or 

branched (C
1
-C
6
)-alkyl group, a phenyl group (unsubstituted 
or substituted by one or more halogen atoms 

or straight-chain or branched (C
1
-C
6
)-alkyl, 
straight-chain or branched (C
1
-C
6
)-alkoxy or 
trihalomethyl groups), a benzyl group, a pyridylmethyl 

group, or an imidazolylmethyl, thiazolylmethyl, 
pyridyl, imidazolyl or thiazolyl group, 
 
or 


R
1
 and R
2
form together with the carbon atoms to which 
they are attached a cyclopentane or cyclohexane ring, 
R
3
represents a hydroxy group, a straight-chain or 
branched (C
1
-C
6
)-alkoxy group or amino (unsubstituted 
or substituted by one or two straight-chain or 

branched (C
1
-C
6
)-alkyl groups), 
R
4
represents a straight-chain or branched (C
1
-C
6
)-alkyl 
group, a phenyl group (unsubstituted or substituted by 

one or more halogen atoms or straight-chain or 
branched (C
1
-C
6
)-alkyl, straight-chain or branched  
 

(C
1
-C
6
)-alkoxy, trihalomethyl or hydroxy groups), a 
naphthyl group, a pyridyl group, a thienyl group or a 

thiazolyl group, 
X
represents a methylene group or an oxygen or sulphur 
atom, 
 
the enantiomers thereof, and also the addition salts 

thereof with a pharmaceutically acceptable base. 
Compounds of formula (I) according to claim 1, 

wherein R
1
 represents a hydrogen atom or a methyl group. 
Compounds of formula (I) according to claim 1 wherein 
R
2
 represents a methyl group. 
Compounds of formula (I) according to claim 1 
wherein X represents a methylene group. 
Compound of formula (I) according to claim 1 which 
is {6-[(4-chlorophenylsulphonyl)amino]
-2-methyl-5,6,7,8-tetrahydronaphth-1-yl}propionic 
acid, and also the 

addition salts thereof with a pharmaceutically acceptable 
base. 
Process for the preparation of compounds of formula 
(I) according to claim 1 wherein X represents a methylene 

group, characterised in that there is used as starting 
material a sulphonyl chloride of formula (II) : 


R
4
-SO
2
Cl
 
wherein R
4
 is as defined for formula (I),
 
which is reacted in basic medium :
either
with a cyclohexylamine of formula (III) :  
 


 
(prepared from the corresponding cyclohexanone by 

reaction, under an inert atmosphere, with benzylamine 
in the presence of sodium triacetoxyborohydride 

followed by hydrogenolysis)
 
to yield the compound of formula (IV) : 


 
wherein R
4
 is as defined for formula (I), 
or
with 4-aminocyclohexanol,
 
to yield the compound of formula (V) : 


 
wherein R
4
 is as defined for formula (I),
 
which is oxidised with the aid of Jones reagent 

(chromic acid in acetone and aqueous sulphuric 
acid),
 
to yield the compound of formula (IV) described 

above, 
 
which compound of formula (IV) is reacted with ethyl 

formate in the presence of sodium hydride
 
to yield the compound of formula (VI) :  

 

 
wherein R
4
 is as defined for formula (I),
 
which is then subjected, depending on the nature of the 

compounds of formula (I) it is desired to obtain, to the 
action of an alkoxycarbonylmethylenetriphenylphosphorane 

optionally substituted in the Î±-position of the ester 
group by a halogen atom, a straight-chain or branched 

(C
1
-C
6
)-alkyl group, a phenyl group (unsubstituted or 
substituted by one or more halogen atoms or straight-chain 

or branched (C
1
-C
6
)-alkyl, straight-chain or 
branched (C
1
-C
6
)-alkoxy or trihalomethyl groups), a 
benzyl group, a pyridylmethyl group or by an imidazolylmethyl 

group,
 
to yield the compound of formula (VII) : 


 
wherein R
1
 and R
4
 are as defined for formula (I) and R 
represents a straight-chain or branched (C
1
-C
6
)-alkyl 
group,
 
which is then subjected to reaction with p-toluene-sulphonic 

acid or trifluoroacetic acid
 
to yield the compound of formula (VIII) :  

 

 
wherein R
1
 and R
4
 are as defined for formula (I),
 
which is subjected to a Diels-Alder reaction with a 

suitably substituted alkyl alk-2-ynoate
 
to yield, after possible rearrangement, the compound of 

formula (IX) : 

 
wherein R
1
, R
2
 and R
4
 are as defined for formula (I),
 
which is subjected to the action of lithium aluminium 

hydride in anhydrous medium
 
to yield the compound of formula (X) : 


 
wherein R
1
, R
2
 and R
4
 are as defined for formula (I),
  
 

which is reacted with an oxidizing agent, such as 4-benzylpyridinium 
dichromate,
 
to yield the aldehyde of formula (XI) : 


 
wherein R
1
, R
2
 and R
4
 are as defined for formula (I),
 
which is reacted with (methoxycarbonylmethylene)triphenylphosphorane
 
to yield the compound of formula (XII): 


 
wherein R
1
, R
2
 and R
4
 are as defined for formula (I),
 
which is reduced with the aid of samarium iodide in the 

presence of methanol
 
to yield the compound of formula (XIII) : 


  
 

wherein R
1
, R
2
 and R
4
 are as defined for formula (I),
 
which is then converted into the corresponding acid, 

ester or amide according to a conventional technique of 
organic chemistry,
 
to yield the compound of formula (I/a), a particular case 

of compounds of formula (I) : 

 
wherein R
1
, R
2
, R
3
 and R
4
 are as defined for formula (I), 

which may, where necessary, be purified according to a 
conventional purification technique, 
which is separated, where appropriate, into its 
isomers according to a conventional separation 

technique, 
which is converted, if desired, into its addition 
salts with a pharmaceutically acceptable base. 
Process for the preparation of compounds of formula 
(I) according to claim 1 wherein R
1
 and R
2
 represent a 
hydrogen atom and X represents a methylene group,
 
characterised in that there is used as starting material 

a compound of formula (XIV) : 

 
which is reacted with excess methyl acrylate in the 

presence of a catalytic amount of palladium acetate and  
 

tri-ortho-tolylphosphine in triethylamine,
 
to yield the compound of formula (XV) : 


 
which is converted by reaction with benzylamine, in the 

presence of sodium triacetoxyborohydride, into the 
compound of formula (XVI) : 


 
which is subjected to catalytic hydrogenation to yield 

the compound of formula (XVII) : 

 
which is reacted in basic medium with a sulphonyl 

chloride of formula (II) : 

R
4
SO
2
Cl
 
wherein R
4
 is as defined for formula (I),
 
to yield the compound of formula (XVIII) :  

 

 
wherein R
4
 is as defined for formula (I),
 
which is then converted into the corresponding acid, 

ester or amide according to a conventional technique of 
organic chemistry,
 
to yield the compound of formula (I/b), a particular 

case of compounds of formula (I) : 

 
wherein R
3
 and R
4
 are as defined for formula (I), 

which may, where necessary, be purified according to a 
conventional purification technique, 
which is separated, where appropriate, into its 
isomers according to a conventional separation 

technique, 
which is converted, if desired, into its addition 
salts with a pharmaceutically acceptable base. 
Process for the preparation of compounds of formula 
(I) according to claim 1 wherein X=X' represents a 

sulphur or oxygen atom, characterised in that there is 
used as starting material a compound of formula (XIX) :  

 

 
wherein R
1
 and R
2
 are as defined for formula (I) and X' 
represents a sulphur or oxygen atom,
 
which is cyclised in the presence of polyphosphoric acid
 
to yield the compound of formula (XX) : 


 
wherein R
1
, R
2
 and X' are as defined above,
 
which is reacted with excess methyl acrylate in the 

presence of a catalytic amount of palladium acetate and 
tri-ortho-tolylphosphine in triethylamine,
 
to yield the compound of formula (XXI) : 


 
wherein R
1
, R
2
 and X' are as defined above,
 
which is reacted with hydroxylamine, then with tosyl 

chloride and finally is subjected to Neber rearrangement
 
to yield the compound of formula (XXII) :  

 

 
wherein R
1
, R
2
 and X' are as defined above,
 
which is then subjected to reduction in the presence of a 

catalyst to yield the compound of formula (XXIII) : 

 
wherein R
1
, R
2
 and X' are as defined above,
 
which is reacted in basic medium with a sulphonyl 

chloride of formula (II) : 

R
4
SO
2
Cl
 
wherein R
4
 is as defined for formula (I),
 
to yield the compound of formula (XXIV) : 


 
wherein R
1
, R
2
, R
4
 and X' are as defined above,
 
which is then converted into the corresponding acid, 

ester or amide according to a conventional technique of 
organic chemistry,
  
 

to yield the compound of formula (I/c), a particular case 
of compounds of formula (I) : 


 
wherein R
1
, R
2
, R
3
, R
4
 and X' are as defined above, 

which may, where necessary, be purified according to a 
conventional purification technique, 
which is separated, where appropriate, into its 
isomers according to a conventional separation 

technique, 
which is converted, if desired, into its addition 
salts with a pharmaceutically acceptable base. 
Process for the preparation of compounds of formula 
(I) according to claim 1 wherein X represents a methylene 

group, R
1
 represents a methyl group and R
2
 represents a 
hydrogen atom, characterised in that there is used as 

starting material 1,3-cyclohexanedione which is reacted 
with tiglic aldehyde to yield the compound of 

formula (XXV) : 

 
which is reacted with an alkyl propiolate to yield the 

compound of formula (XXVI) :  
 


 
wherein alk represents an alkyl group, which is reacted 

with hydroxylamine, then with tosyl chloride and finally 
is subjected to Neber rearrangement
 
to yield the compound of formula (XXVII) : 


 
wherein alk is as defined above, which is then subjected 

to catalytic reduction, and subsequently to the action of 
a sulphonyl chloride of formula (II) according to claim 

6,
 
to yield the compound of formula (XXVIII) : 


 
wherein R
4
 and alk are as defined above,
 
which compound of formula (XXVIII) is then subjected to 

the sequence of reactions according to claim 6 described 
for the conversion of the compound of formula (IX) into 

the compound of formula (I/a), and yields the corresponding 
compound of formula (I). 
Pharmaceutical compositions comprising as active  
 

ingredient at least one compound according to any one of 
claims 1 to 5, alone or in combination with one or more 

pharmaceutically acceptable, inert, non-toxic carriers. 
Pharmaceutical composition according to claim 10, 
comprising at least one active ingredient according to 

any one of claims 1 to 5 for use as an antithrombotic 
agent. 
</CLAIMS>
</TEXT>
</DOC>
